Inflammation  >>  Imjudo (tremelimumab) 
Welcome,         Profile    Billing    Logout  

5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imjudo (tremelimumab) / AstraZeneca, Pfizer
16-C-0135, NCT02821754: A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Completed
2
54
US
Durvalumab, Imfinzi, Tremelimumab, Ticilimumab, Trans-arterial Catheter Chemoembolization (TACE), TACE, Radiofrequency Ablation (RFA), RFA, Cryoablation, Cryosurgery
National Cancer Institute (NCI)
Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
02/21
12/22
RICE, NCT04159974: Radio-Immuno-Chemotherapy of Cancer of the Esophagus

Active, not recruiting
2
56
Europe
Durvalumab 50 MG/ML, Tremelimumab
University of Cologne, AstraZeneca
Esophageal Adenocarcinoma
06/24
06/24
NCT03206073: A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Checkmark Results in combination with Pexa-Vec with failed MSS and MSI-H colorectal cancer
Jan 2019 - Jan 2019: Results in combination with Pexa-Vec with failed MSS and MSI-H colorectal cancer
Completed
1/2
34
US
Durvalumab, MEDI-4736, Tremelimumab, CP-675,206, Pexa-Vec, Pexa-Vec, INN pexastimogene devacirepvec
National Cancer Institute (NCI)
Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma, Refractory Cancer, Colorectal Neoplasms
09/20
06/22
NCT03275597: Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Terminated
1
17
US
Durvalumab, 1428935-60-7, D10808, Tremelimumab, 745013-59-6, QEN1X95CIX, Stereotactic Body Radiotherapy, SRBT, stereotactic ablative radiotherapy, SABR
University of Wisconsin, Madison, AstraZeneca
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IV
07/20
07/20
MITRE, NCT04107168: Microbiome Immunotherapy Toxicity and Response Evaluation

Recruiting
N/A
1800
Europe
Nivolumab, Opdivo, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Durvalumab, Imfinzi, Tremelimumab, CP-675,206, Atezolizumab, Tecentriq, Bevacizumab, Avastin
CCTU- Cancer Theme, Microbiotica Ltd
Melanoma, Renal Cancer, Lung Cancer
07/24
07/25

Download Options